Related Experiment Videos
[The value of dobutamine in cardiology]
Insights
Dobutamine significantly improves cardiac function and reduces vascular resistance in patients with low output syndrome and left ventricular failure. Its hemodynamic benefits support its use in acute myocardial infarction and other cardiac conditions.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Low output syndrome and left ventricular failure present significant clinical challenges.
- Dobutamine is a sympathomimetic amine used to treat cardiac dysfunction.
Purpose of the Study:
- To evaluate the hemodynamic effects of dobutamine in patients with low output syndrome.
- To assess the safety and efficacy of dobutamine for prolonged use and in acute myocardial infarction.
Main Methods:
- Hemodynamic parameters were assessed via cardiac catheterization in 17 patients.
- Nine patients received prolonged treatment with dobutamine at 8 microgram/kg/min.
- Continuous monitoring included arterial pressure, heart rate, and cardiac output.
Main Results:
- Dobutamine significantly increased cardiac index, systolic index, myocardial contractility (dp/dt, Vmax), and systolic work index.
- Mean aortic pressure and heart rate showed minimal increases.
- Left ventricular end-diastolic pressure, systemic, and pulmonary vascular resistance significantly decreased.
- Hemodynamic improvements were consistent in both short-term and prolonged treatment groups.
Conclusions:
- Dobutamine is effective in improving hemodynamic function in low output syndromes with left ventricular failure, regardless of etiology.
- The drug's favorable hemodynamic profile and minimal impact on myocardial excitability suggest its utility in acute myocardial infarction.
- Dobutamine may be considered for prolonged use in managing severe heart failure and cardiogenic shock.
Abstract:
The hemodynamic effects of dobutamine have been evaluated by catheterization for a limited duration in 17 patients. The cardiac index, the systolic index, the myocardial contractility given by the values dp/dt and Vmax, and the systolic work index have increased significantly while the increase in the mean aortic pressure and the cardiac rate were small. The left ventricular telediastolic pressure, and systemic and pulmonary arterial resistance diminished significantly. These results seen to authorise the prolonged use of this drug in the low output syndromes with left ventricular failure whether the cause be ischemic or due to a cardiomyopathy. Nine patients were then treated, with a dosage of 8 microgram/kg/min. The supervision of the treatment was composed of iterative readings of the arterial pressure, the cardiac rate, pulmonary capillary and arterial pressures, and the cardiac index. The hemodynamic results were similar to those obtained in the 17 patients. It seems that this product can be used in the acute stage of myocardial infarction. Indeed its action on the myocardial excitability is small and the moderate increase in the oxygen consumption can be compensated for by the improvement in the myocardial vascularisation.